Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Harm Jan Lourens"'
Autor:
Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer, Valerie R. Wiersma
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Acute myeloid leukemia (AML) is a malignancy still associated with poor survival rates, among others, due to frequent occurrence of therapy-resistant relapse after standard-of-care treatment with cytarabine (AraC). AraC triggers apoptotic ce
Externí odkaz:
https://doaj.org/article/744707850025474188f77817ec125057
Autor:
Nienke Visser, Levi Collin Nelemans, Yuan He, Harm Jan Lourens, Macarena González Corrales, Gerwin Huls, Valerie R. Wiersma, Jan Jacob Schuringa, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In recent years, the therapeutic (re)activation of innate anticancer immunity has gained prominence, with therapeutic blocking of the interaction of Signal Regulatory Protein (SIRP)-α with its ligand CD47 yielding complete responses in refractory an
Externí odkaz:
https://doaj.org/article/433d8659aff946d7b49c0e7573e80c22
Autor:
Jimena Álvarez Freile, Yuzhu Qi, Lisa Jacob, Maria Franceskin Lobo, Harm Jan Lourens, Gerwin Huls, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Investigations into the strength of antigen-specific responses in vitro is becoming increasingly relevant for decision making in early-phase research of novel immunotherapeutic approaches, including adoptive cell but also immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/6a90fd200f114efda1abe01601dbe684
Autor:
Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
A higher density of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment, particularly cytotoxic CD8+ T cells, is associated with improved clinical outcome in various cancers. However, local inhibitory factors can suppress T cell activ
Externí odkaz:
https://doaj.org/article/1dd027660af844b49d8b8cf3bd413551
Autor:
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cell
Externí odkaz:
https://doaj.org/article/5b0c52b51ccf44eb9aa17073f9d75dfd
Autor:
Yuan He, Renee Bouwstra, Valerie R. Wiersma, Mathilde de Jong, Harm Jan Lourens, Rudolf Fehrmann, Marco de Bruyn, Emanuele Ammatuna, Gerwin Huls, Tom van Meerten, Edwin Bremer
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-8 (2019)
CD47 is a promising new target in cancer immunotherapy and recently the pro-phagocytic signal SLAMF7 has been shown to have a crucial role in phagocytosis induced by CD47-blocking antibody in hematological tumors. In this study, the authors demonstra
Externí odkaz:
https://doaj.org/article/69bb46c6cb07419c8c3da1b05f0247bc
Autor:
Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer
Publikováno v:
Biomedicines, Vol 10, Iss 5, p 1175 (2022)
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison t
Externí odkaz:
https://doaj.org/article/1da5f0a70400457ca37c839a7d7747c6
Autor:
Natasha Ustyanovska Avtenyuk, Ghizlane Choukrani, Emanuele Ammatuna, Toshiro Niki, Ewa Cendrowicz, Harm Jan Lourens, Gerwin Huls, Valerie R. Wiersma, Edwin Bremer
Publikováno v:
Biomedicines, Vol 10, Iss 1, p 66 (2021)
In earlier studies, galectin-9 (Gal-9) was identified as a multifaceted player in both adaptive and innate immunity. Further, Gal-9 had direct cytotoxic and tumor-selective activity towards cancer cell lines of various origins. In the current study,
Externí odkaz:
https://doaj.org/article/2a67e24bf62345e19fde2b58b24c359c
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 5, p 2337 (2021)
Elevated activation of the autophagy pathway is currently thought to be one of the survival mechanisms allowing therapy-resistant cancer cells to escape elimination, including for cytarabine (AraC)-resistant acute myeloid leukemia (AML) patients. Con
Externí odkaz:
https://doaj.org/article/5921a5ebb62f4e66960a2d8c0cde240f
Autor:
Jimena Alvarez Freile, Yuzhu Qi, Lisa Jacob, Maria Franceskin Lobo, Harm Jan Lourens, Gerwin Huls, Edwin Bremer
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::326a6db8f227dddf697de2e9e1f43b35
https://doi.org/10.1136/jitc-2022-sitc2022.0989
https://doi.org/10.1136/jitc-2022-sitc2022.0989